View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, June 4 (HealthDay News) -- Many individuals taking bisphosphonates are unfamiliar with potential adverse events associated with treatment and with the duration of treatment, according to a study in the May 1 issue of the Journal of the American Dental Association.
Cesar A. Migliorati, D.D.S., of Nova Southeastern University in Fort Lauderdale, Fla., and colleagues evaluated individuals between June 2008 and April 2009 seeking routine dental care and being treated with bisphosphonates. The knowledge of each individual was assessed regarding indications for bisphosphonate treatment, duration of treatment, and whether they had been educated on the risk of possible adverse events associated with treatment.
Of the 73 individuals interviewed, the researchers note that 84 percent said they understood why they were being prescribed bisphosphonate therapy. However, 82 percent were unable to remember if they had been educated by their prescribing physician on the risk of adverse events such as oral osteonecrosis, and 80 percent were unsure about the duration of treatment.
"We believe that a more effective communication process between prescribing physicians, dentists and patients using bisphosphonates is needed," the authors write.
Migliorati serves as a consultant for Amgen.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top